1.37
0.74%
+0.01
Pre-market:
1.36
-0.01
-0.73%
Akebia Therapeutics Inc. stock is currently priced at $1.37, with a 24-hour trading volume of 2.08M.
It has seen a +0.74% increased in the last 24 hours and a -36.87% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.37 pivot point. If it approaches the $1.39 resistance level, significant changes may occur.
Previous Close:
$1.36
Open:
$1.38
24h Volume:
2.08M
Market Cap:
$286.84M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-2.6346
EPS:
-0.52
Net Cash Flow:
$-23.38M
1W Performance:
-2.14%
1M Performance:
-36.87%
6M Performance:
+63.15%
1Y Performance:
+107.54%
Akebia Therapeutics Inc. Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc.
Sector
Industry
Phone
617-871-2098
Address
245 First Street, Suite 1100, Cambridge, MA
Akebia Therapeutics Inc. Stock (AKBA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
Mar-31-22 | Downgrade | Needham | Buy → Hold |
Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-14-19 | Reiterated | Needham | Buy |
Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
May-02-19 | Initiated | JP Morgan | Overweight |
Mar-20-19 | Initiated | Citigroup | Neutral |
Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
Aug-10-18 | Reiterated | Needham | Buy |
Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
Dec-19-17 | Initiated | Piper Jaffray | Overweight |
Dec-07-17 | Initiated | BTIG Research | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
Apr-27-17 | Reiterated | Needham | Buy |
Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
Nov-15-16 | Initiated | Aegis Capital | Buy |
Sep-29-16 | Initiated | Brean Capital | Buy |
Mar-16-16 | Reiterated | Needham | Buy |
Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc. Stock (AKBA) Latest News
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Benzinga
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Zacks Investment Research
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Zacks Investment Research
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Zacks Investment Research
Akebia Therapeutics Inc. Stock (AKBA) Financials Data
Akebia Therapeutics Inc. (AKBA) Revenue 2024
AKBA reported a revenue (TTM) of $194.75 million for the quarter ending December 31, 2023, a -33.43% decline year-over-year.
Akebia Therapeutics Inc. (AKBA) Net Income 2024
AKBA net income (TTM) was -$51.26 million for the quarter ending December 31, 2023, a +44.96% increase year-over-year.
Akebia Therapeutics Inc. (AKBA) Cash Flow 2024
AKBA recorded a free cash flow (TTM) of -$23.38 million for the quarter ending December 31, 2023, a +68.08% increase year-over-year.
Akebia Therapeutics Inc. (AKBA) Earnings per Share 2024
AKBA earnings per share (TTM) was -$0.28 for the quarter ending December 31, 2023, a +47.17% growth year-over-year.
About Akebia Therapeutics Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):